Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer

医学 近距离放射治疗 核医学 宫颈癌 放射治疗计划 剂量率 直肠 剂量学 四分位间距 放射治疗 放射科 癌症 医学物理学 外科 内科学
作者
Pierre Annède,Isabelle Dumas,Antoine Schernberg,Anne Tailleur,I. Fumagalli,Sophie Bockel,Fabien Mignot,Manon Kissel,Éric Deutsch,Christine Haie‐Meder,Cyrus Chargari
出处
期刊:Brachytherapy [Elsevier]
卷期号:18 (3): 370-377 被引量:10
标识
DOI:10.1016/j.brachy.2018.12.009
摘要

Only scarce data are available on the possibility to include radiobiological optimization as part of the dosimetric process in cervical cancer treated with brachytherapy (BT). We compared dosimetric outcomes of pulse-dose-rate (PDR) and high-dose-rate (HDR)-BT, according to linear-quadratic model.Three-dimensional dosimetric data of 10 consecutive patients with cervical cancer undergoing intracavitary image-guided adaptive PDR-BT after external beam radiation therapy were examined. A new HDR plan was generated for each patient using the same method as for the PDR plan. The procedure was intended to achieve the same D90 high-risk clinical target volume with HDR as with PDR planning after conversion into dose equivalent per 2 Gy fractions (EQD2) following linear-quadratic model. Plans were compared for dosimetric variables.As per study's methodology, the D90 high-risk clinical target volume was strictly identical between PDR and HDR plans: 91.0 Gy (interquartile: 86.0-94.6 Gy). The median D98 intermediate-risk clinical target volume was 62.9 GyEQD2 with HDR vs. 65.0 GyEQD2 with PDR (p < 0.001). The median bladder D2cc was 65.6 GyEQD2 with HDR, vs. 62 GyEQD2 with PDR (p = 0.004). Doses to the rectum, sigmoid, and small bowel were higher with HDR plans with a median D2cc of 55.6 GyEQD2 (vs. 55.1 GyEQD2, p = 0.027), 67.2 GyEQD2 (vs. S 64.7 GyEQD2, p = 0.002), and 69.4 GyEQD2 (vs. 66.8 GyEQD2, p = 0.014), respectively. For organs at risk (OARs), the effect of radiobiological weighting depended on the dose delivered. When OARs BT contribution to D2cc doses was <20 GyEQD2, both BT modalities were equivalent. OARs EQD2 doses were all higher with HDR when BT contribution to D2cc was ≥20 GyEQD2.Both BT modalities provided satisfactory target volume coverage with a slightly higher value with the HDR technique for OARs D2cc while intermediate-risk clinical target volume received higher dose in the PDR plan. The radiobiological benefit of PDR over HDR was predominant when BT contribution dose to OARs was >20 Gy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
西梅发布了新的文献求助10
2秒前
4秒前
暖冬22发布了新的文献求助10
4秒前
景穆完成签到,获得积分10
5秒前
5秒前
仁仁仁完成签到,获得积分10
6秒前
6秒前
7秒前
coco完成签到,获得积分20
7秒前
完美世界应助lulu采纳,获得10
8秒前
xz完成签到,获得积分10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
浮游应助科研通管家采纳,获得10
8秒前
大模型应助科研通管家采纳,获得10
8秒前
8秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
彭于晏应助科研通管家采纳,获得20
8秒前
星辰大海应助科研通管家采纳,获得10
8秒前
9秒前
Orange应助科研通管家采纳,获得10
9秒前
Livrik发布了新的文献求助10
9秒前
英俊的铭应助科研通管家采纳,获得10
9秒前
上官若男应助科研通管家采纳,获得10
9秒前
ltxinanjiao发布了新的文献求助10
9秒前
Akim应助科研通管家采纳,获得10
9秒前
乐乐应助科研通管家采纳,获得10
9秒前
义气千风发布了新的文献求助10
9秒前
liubo发布了新的文献求助10
9秒前
coco发布了新的文献求助10
10秒前
星野发布了新的文献求助10
10秒前
科研通AI5应助科研通管家采纳,获得10
10秒前
xuan应助科研通管家采纳,获得100
10秒前
liuteng完成签到,获得积分10
10秒前
浮游应助科研通管家采纳,获得20
10秒前
汉堡包应助科研通管家采纳,获得10
10秒前
10秒前
李爱国应助科研通管家采纳,获得10
11秒前
科研通AI5应助科研通管家采纳,获得10
11秒前
高分求助中
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
哈工大泛函分析教案课件、“72小时速成泛函分析:从入门到入土.PDF”等 660
Theory of Dislocations (3rd ed.) 500
Comparing natural with chemical additive production 500
The Leucovorin Guide for Parents: Understanding Autism’s Folate 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5227238
求助须知:如何正确求助?哪些是违规求助? 4398359
关于积分的说明 13689318
捐赠科研通 4263055
什么是DOI,文献DOI怎么找? 2339509
邀请新用户注册赠送积分活动 1336803
关于科研通互助平台的介绍 1292920